PharmaTutor (June- 2014)
ISSN: 2347 - 7881
Received On: 07/04/2014; Accepted On: 15/04/2014; Published On: 01/06/2014
AUTHORS: U. A. Deokate, A. M. Gorde*
Dept. Of Pharmaceutical Chemistry,
Government College of Pharmacy, Hotel Vedant Road, Osmanpura,
Aurangabad, Maharashtra, India 431005
*gordeanjali@gmail.com
ABSTRACT:
This review discusses the regulatory aspects of forced degradation and methodology aspects for degradant investigations. It also focuses on the prediction of degradation products and pathways and development of stability indicating assay method. While reviewing the analytical perspectives various conventional and hyphenated techniques for degradant separation and characterization are described in detail.
How to cite this article: UA Deokate, AM Gorde; Forced degradation and Stability Testing: Strategies and Analytical Perspectives; PharmaTutor; 2014; 2(6); 61-74
[ABSTRACT WITH CITATION] [VIEW AS HTML
REFERENCES:
1.R.N. Rao, A.N. Raju and R. Narsimha: Isolation and characterization of process related impurities and degradation products of bicalutamide and development of RP-HPLC method for impurity profile study. Journal of Pharmaceutical and Biomedical Analysis 2008; 46:505–519.
2.Deepti Jain and Pawan Kumar Basniwal: Forced degradation and impurity profiling: Recent trends in analytical perspectives. Journal of Pharmaceutical and Biomedical Analysis 2013; 86:11–35.
3.Saranjit Singh, Tarun Handa, Mallikarjun Narayanam, Archana Sahu, Mahendra Junwal and Ravi P. Shah: A critical review on the use of modern sophisticated hyphenated tools in the characterization of impurities and degradation products. Journal of Pharmaceutical and Biomedical Analysis 2012; 69:148– 173
4.Abolghasem Jouyban and Hamed Parsa: Genotoxic Impurities in Pharmaceuticals. Chapter no. 17, Toxicity and Drug Testing.
5.Blessy M1, Ruchi D Patel and Prajesh N Prajapati, Y K Agrawal: Development of forced degradation and stability indicating studies of drugs: A review. Journal of Pharmaceutical Analysis 2013; 09:003
6.ICH harmonised tripartite guideline stability testing of new drug substances and products Q1A (R2).
7.Karen M. Alsante, Akemi Ando, Roland Brown, Janice Ensing, Todd D. Hatajik, Wei Kong and Yoshiko Tsuda: The role of degradant profiling in active pharmaceutical ingredients and drug products. Advanced Drug Delivery Reviews 2007; 59:29–37.
8.Szepesi G: Selection of High-performance liquid chromatographic methods in pharmaceutical analysis. Journal of Chromatography 1989; 464:265-278.
9.Carr GP and Wahlich JC: A practical approach to method validation in pharmaceutical analysis. Journal of Pharmaceutical and Biomedical Analysis 1990; 86:613-618.
10.Jenke DR: Chromatographic method validation: a review of common practices and procedures II. Journal of Liquid Chromatography 1996; 19:737-757.
11.George Ngwa: Forced degradation as an integral part of HPLC stability-indicating method development. Drug delivery technology June 2010; vol.10, no. 5.
12.Dr. Hildegard Brümmer: How to approach a forced degradation study. Issue no.31, Life science technical bulletin January 2011.
13.S.Singh and M.Bakshi: Guidance on conduct of stress tests to determine inherent stability of drugs. Pharmaceutical Technology 2000; 24:1–14.
14.K.M. Alsante, A.Ando and R.Brown: The role of degradant profiling in active pharmaceutical ingredients and drug products. Advanced Drug Delivery Reviews 2007; 59(1):29–37.
15.Cheekatla S, Ravichandrababu R, and Reddy BN: Determination and characterization of degradation products of Anastrozole by LC–MS/MS and NMR spectroscopy. Journal of Pharmaceutical and Biomedical Analysis 2011; 56: 962-968.
16.Gupta A, Yadav JS, Rawat S and Gandhi M: Method Development and Hydrolytic Degradation Study of Doxofylline by RP-HPLC and LC-MS/MS. Asian Journal of Pharmaceutical Analysis 2011; 1:14-18.
17.ICH Harmonised Tripartite Guideline stability testing: Photostability testing of new drug substances and products Q1B .
18.Baertschi SW and Alsante KM: Stress testing: The chemistry of the drug degradation, pp: 99, in; Pharmaceutical Stress Testing, Baertschi SW, editors, Taylor & Francis, New York. 2005.
19.Ranjit Singh and Zia ur Rehman: Current trends in forced degradation study for pharmaceutical product development. Journal of Pharmaceutical Education and Research June 2012; vol.3, issue no.1.
20.Qiu F Norwood DL: Identification of pharmaceutical impurities. Journal of Liquid Chromatography R T 2007; 30: 877-935.
21.Boccardi G: Oxidative susceptibility testing, pp: 220. In; pharmaceutical Stress Testing Predicting Drug Degradation; Baertschi SW, editors, Taylor and Francis, New York. 2005.
22.Alsante KM, Hatajik TD, Lohr LL, Santafianos D and Sharp TR: Solving impurity/degradation problems: case studies. pp: 380, In; Handbook of Isolation and Characterization of impurities in Pharmaceutical, Ahuja S, Alsante K, editors, Academics Press, New York. 2003.
23.ICH Harmonised Tripartite Guideline stability testing of new drug substances and products Q1A (R2).
24.Dorman DE, Lornez LJ, Occolowitz JL, Spangle LA, Collins, MW, Bashore FN and Baertschi SW: Isolation and structure elucidation of the major degaradtion products of cefaclor in the solid state. Journal of Pharmaceutical Science 1997; 86: 526-539
25.Trabelsi H, Hassen IE, Bouabdallah S, Bouzouita K and Safta F: Stability indicating LC method for determination of Pipamperone. Journal of Pharmaceutical and Biomedical Analysis 2005; 39: 914-919.
26.Bojana Prekodravac, Markus Damm and C. Oliver Kappe: Microwave-assisted forced degradation using high-throughput microtiter Platforms. Journal of Pharmaceutical and Biomedical Analysis 2011; 56:867– 873.
27.T.D. Salatin and W.L. Jorgensen: Computer-assisted mechanistic evaluation of organic reactions: Overview. Journal of Organic Chemistry 1980; 45:2043–2051.
28.W.L. Jorgensen, E.R. Laird, A.J. Gushurst, J.M. Fleischer, M. Jan, S.A. Gothe, H.E. Helson, G.D. Paderes and S. Sinclair: CAMEO: A program for the logical prediction of the products of organic reactions. Pure Applied Chemistry 1990; 62:1921–1932.
29.J.M. Fleischer, A.J. Gushurst and W.L. Jorgensen: Computer-assisted mechanistic evaluation of organic reactions. 26: Diastereoselective additions: Cram’s Rule. Journal of Organic Chemistry 1995; 60:490-498.
30.S.A. Gothe, H.E. Helson, I. Houdaverdis, I. Lagerstedt, S. Sinclair and W.L. Jorgensen: Computer-assisted mechanistic evaluation of organic reactions: 22. The generation and use of three-dimensional structures. Journal of Organic Chemistry 1993; 58:5081–5094.
31.D.L. Pole, H.Y. Ando and S.T. Murphy: Prediction of drug degradants using DELPHI: an expert system for focusing knowledge. Molecular Pharmaceutics 2007; 4:539–549.
32.Christopher Foti, Karen Alsante, Guilong Cheng, Todd Zelesky and Mark Zell: Tools and workflow for structure elucidation of drug degradation products. Trends in Analytical chemistry 2013 49:89–99.
33.Martin A. Ott, Rob L. Toy and William G. Button: An Approach toward the Prediction of Chemical Degradation Pathways. Lhasa Limited, 22-23 Blenheim Terrace, Woodhouse Lane, Leeds LS2 9HD, United Kingdom.
34.S.W. Baertschi, K.M. Alsante and D. Santafianos: Stress testing: The chemistry of drug degradation, in: S.W. Baertschi, K.M. Alsante, R.A. Reed (Eds.), Pharmaceutical Stress Testing: Predicting Drug Degradation, second ed., Informa Health Care, New York, 2011; pp. 49–141.
35.M. Li: Organic Chemistry of Drug Degradation, RCS Publishing, Cambridge, 2012.
36.K.C. Waterman, R.C. Adami, K.M. Alsante, J. Hong, M.S. Landis, F. Lombardo and C.J. Roberts: Stabilization of pharmaceuticals to oxidative degradation. Pharmaceutical Development and Technology 2002; 7:1–32.
37.H.H. Tonnesson: Photostability of Drugs and Drug Formulations. CRC Press, Boca Raton, 1996.
38.K.M. Alsante, T.D. Hatajik, L.L. Lohr and T.R. Sharp: Isolation and identification of process related impurities and degradation products from pharmaceutical drug candidates. Part I, American Pharmaceutical Review 2001; 4:70–78.
39.Monika Bakshi and Saranjit Singh, Development of validated stability-indicating assay methods-critical review. Journal of Pharmaceutical and Biomedical Analysis 2002; 28:1011–1040.
40.K.A. Connors, G.L. Amidon and V.J. Stella (Eds.): Chemical Stability of Pharmaceuticals. Wiley, New York, 1986.
41.N.H. Anderson (Ed.): Photostability Testing: Design and Interpretation of Tests on Drug Substances and Dosage Forms. Taylor and Francis, London, 1996.
42.ICH, Text on Validation of Analytical Procedures. International Conference on Harmonisation, IFPMA, Geneva, 1994.
43.ICH, Validation of Analytical Procedures: Methodology. International Conference on Harmonisation, IFPMA, Geneva, 1996.
44.FDA, Guidance for Industry: Analytical Procedures and Methods Validation (Draft guidance). Food and Drug Administration, Rockville, MD, 2000.
45.The United States Pharmacopeia, 24th Revision, Asian Edition, United States Pharmacopeial Convention, Inc., Rockville, MD, 2000, pp. 2149–2152.
46.M. Grover, M. Gulati and S. Singh: Journal of Chromatography B: Biomedical Sciences and Application 1998; 708:153–159.
47.M. Grover, M. Gulati, B. Singh, S. Singh: Pharmacy and Pharmacology Communication 2000; 6:355–363.
48.A. Blanchard, C. Lee, B. Nickerson, L. Lohr, A. Jensen, K.M. Alsante, T.R. Sharp, D.P. Santafianos, R. Morris and K.D. Snyder: Identification of low-level degradants in low dose tablets. Journal of Pharmaceutical and Biomedical Analysis 2004; 36:265–275.
49.B.E. Richter: The extraction of analytes from solid samples using accelerated solvent extraction. LCGC 1999; 17:522–528.
50.M.A. Mottaleb, S.D. Sarker: Accelarated solvent extraction for natural products isolation. in: S.D. Sarker, L. Nahar (Eds.), Methods in Molecular Biology, Humana Press, New York, edition 3, 2012, 75–87.
51.R. Hu and Y. Pan: Recent trends in counter-current chromatography. Trends in Analytical Chemistry 2012; 40:15–27.
52. Ranasinghe, R. Ramanathan, J. Ragu, D. Mohammed, J. Celia, W.G. Humphreys and T.V. Olah: Integrated quantitative and qualitative workflow for in vivo bioanalytical support in drug discovery using hybrid Q-TOF-MS. BioAnalysis 2012; 4:511–528.
53.K.M. Alsante, S.W. Baertschi, M. Coutant, B. Marquez, T.R. Sharp and T.C. Zelesky: Degradation and impurity analysis for pharmaceutical drug candidates. in: S. Ahuja and S. Scypinski (Eds.): Handbook of Modern Pharmaceutical Analysis. Academic Press, San Diego, edition 2, 2011, 59–169.
54.M. Malet-Martino and U. Holzgrabe: NMR techniques in biomedical and pharmaceutical analysis. Journal of Pharmaceutical and Biomedical Analysis 2011; 55:1–15.
55.M. Elyashberg, A. Williams and G. Martin: Computer – assisted structure verification and elucidation tools in NMR-based structural elucidation. Progress in Nuclear Magnetic Resonance Spectroscopy 2008 53:1–104.
56.Ernst Bayer, Klaus Albert, Michael Nieder and Edgar Grom: On-line coupling of high-performance liquid chromatography and nuclear magnetic resonance. Journal o f Chromatography1 1979; 86:497-507.
57.N.L. Bochkareva, I.N. Glazkov and I.A. Revelsky: Combination of supercritical fluid extraction and gas chromatography-mass spectrometry: determination of impurities extracted from tablet preparations of the benzodiazepine series. Journal of Analytical Chemistry 2006; 61:1082–1089.
58.D. Djozan, A. Jouyban and J. Norouzi: Ultrasonic assisted SPME coupled with GC and GC-MS using pencil lead as a fiber for monitoring the organic volatile impurities of ceftazidime, Journal of Chromatographic Sciences 2008; 46:680–685.
59.K. Fliszar, J.M. Wiggins, C.M. Pignoli, G.P. Martin and Z. Li: Analysis of organic volatile impurities in pharmaceutical excipients by static headspace capillary gas chromatography. Journal of Chromatography A 2004; 1027:83–91.
60.G.L. McClure: Improved determination of organic volatile impurities in pharmaceutical materials by (USP-467) using automated static headspace GC/MS, PDA. Journal of Pharmaceutical Sciences and Technology 1999; 53:129–136.
61.Y. Liu and C.Q. Hu: Establishment of a knowledge base for identification of residual solvents in pharmaceuticals. Analytica Chimica Acta 2006; 575:246–254.
62.J.L.P. Pavon, M. Del, N. Sanchez, C.G. Pinto, M.E.F. Laespada and B.M. Cordero: Use of mass spectrometry methods as a strategy for detection and determination of residual solvents in pharmaceutical products. Analytical Chemistry 2006; 78:4901–4908.
63.J.L.P. Pavon, M. Del, N. Sanchez, M.E.F. Laespada, C.G. Pinto and B.M. Cordero: Analysis of class 1 residual solvents in pharmaceuticals using headspace programmed temperature vaporization-fast gas chromatography-mass spectrometry. Journal of Chromatography A 2007; 1141:123–130.
64. M.J. Hilhorst, G.W. Somsen, G.J. de Jong: Choice of capillary electrophoresis systems for the impurity profiling of drugs. Journal of Pharmaceutical and Biomedical Analysis 1998; 16:1251–1260.
65.J. Cai, J. Henion: Capillary electrophoresis-mass spectrometry. Journal of Chromatography A 1995; 703:667–692.
66.P. Hommerson, A.M. Khan, T. Bristow, M.W. Harrison, G.J. de Jong and G.W. Somsen: Drug impurity profiling by capillary electrophoresis/mass spectrometry using various ionization techniques. Rapid Communication in Mass Spectrometry 2009; 23:2878–2884.
67.N. Watanabe and E. Niki: Direct-coupling of FT-NMR to high performance liquid chromatography. Proceedings of Japan Academy Series B Physical and Biological Sciences 1978; 54:194–199.
68.K.L. Colson: Ultracool NMR technology. Modern Drug Discovery 2003; 47–51
69.H. Kovacs, D. Moskau and M. Spraul, Cryogenically cooled probes-a leap in NMR technology. Progress in Nuclear Magnetic Resonance Spectroscopy 2005; 46:131–155.
70.A.G. Webb: Microcoil nuclear magnetic resonance spectroscopy. Journal of Pharmaceutical and Biomedical Analysis 2005; 38:892–903.
71.R. Mukhopadhyay: Liquid NMR probes: Oh so many choices. Analytical Chemistry 2007; 79:7959–7963.
72.M. Malet-Martino and U. Holzgrabe: NMR techniques in biomedical and pharmaceutical analysis. Journal of Pharmaceutical and Biomedical Analysis 2011; 55:1–15.
73. G.W. Somsen, C. Gooijer, U.A.T. Brinkman, N.H. Velthorst and T. Visser: Coupling of LC and FT-IR: impurity profiling of testosterone undecanoate. Applied Spectroscopy 1992; 46:1514–1519.
.png)
